175 related articles for article (PubMed ID: 34041820)
1. Chromosome microarray characterisation of chromosome arm 12p loss associated with complex molecular karyotype and recurrent adverse cytogenetic markers in multiple myeloma.
Hung D; Lenton D; Eslick R; Blennerhassett R; Joshi M; McCaughan G; Day S; Wright D
Genes Chromosomes Cancer; 2021 Oct; 60(10):668-677. PubMed ID: 34041820
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients.
Hamdaoui H; Benlarroubia O; Ait Boujmia OK; Mossafa H; Ouldim K; Belkhayat A; Smyej I; Benrahma H; Dehbi H; Chegdani F
Mol Genet Genomic Med; 2020 Sep; 8(9):e1363. PubMed ID: 32573970
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of the i(12p) marker chromosome in germ cell tumors.
Bosl GJ; Ilson DH; Rodriguez E; Motzer RJ; Reuter VE; Chaganti RS
J Natl Cancer Inst; 1994 Mar; 86(5):349-55. PubMed ID: 8308927
[TBL] [Abstract][Full Text] [Related]
5. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.
Chang H; Li D; Zhuang L; Nie E; Bouman D; Stewart AK; Chun K
Leuk Lymphoma; 2004 May; 45(5):965-9. PubMed ID: 15291356
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.
Harrison CJ; Mazzullo H; Cheung KL; Gerrard G; Jalali GR; Mehta A; Osier DG; Orchard KH
Br J Haematol; 2003 Mar; 120(6):944-52. PubMed ID: 12648063
[TBL] [Abstract][Full Text] [Related]
7. Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes.
Mohamed AN; Bentley G; Bonnett ML; Zonder J; Al-Katib A
Am J Hematol; 2007 Dec; 82(12):1080-7. PubMed ID: 17654686
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence in situ hybridization analyses of hematologic malignancies reveal frequent cytogenetically unrecognized 12p rearrangements.
Andreasson P; Johansson B; Billström R; Garwicz S; Mitelman F; Höglund M
Leukemia; 1998 Mar; 12(3):390-400. PubMed ID: 9529134
[TBL] [Abstract][Full Text] [Related]
9. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetics of multiple myeloma.
Trcić RL; Skelin IK; Sustercić D; Planinc-Peraica A; Ajduković R; Haris V; Kusec R; Begović D
Coll Antropol; 2010 Mar; 34(1):41-4. PubMed ID: 20432732
[TBL] [Abstract][Full Text] [Related]
11. Molecular cytogenetic characterization of breakpoints in 19 patients with hematologic malignancies and 12p unbalanced translocations.
Odero MD; Carlson K; Lahortiga I; Calasanz MJ; Rowley JD
Cancer Genet Cytogenet; 2003 Apr; 142(2):115-9. PubMed ID: 12699886
[TBL] [Abstract][Full Text] [Related]
12. CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.
Haferlach C; Bacher U; Kohlmann A; Schindela S; Alpermann T; Kern W; Schnittger S; Haferlach T
Haematologica; 2011 Jun; 96(6):829-36. PubMed ID: 21422114
[TBL] [Abstract][Full Text] [Related]
13. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
14. [Molecular cytogenetic analyses of patients with plasma cell myeloma in Tolna and Baranya counties in Hungary].
Kosztolányi S; Horváth B; Hosnyánszki D; Kereskai L; Sziládi E; Jáksó P; Alizadeh H; Szuhai K; Alpár D; Kajtár B
Orv Hetil; 2019 Jun; 160(24):944-951. PubMed ID: 31433233
[TBL] [Abstract][Full Text] [Related]
15. [Application of fluorescence in-situ hybridization technique in multiple myeloma].
Zhao Y; Zheng D; Li J; Zhu WT
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):459-64. PubMed ID: 19830857
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India.
Govindasamy P; Pandurangan P; Tarigopula A; Mani R; R Samuel C
Asian Pac J Cancer Prev; 2019 Jan; 20(1):235-241. PubMed ID: 30678438
[TBL] [Abstract][Full Text] [Related]
17. Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study.
Lange K; Gadzicki D; Schlegelberger B; Göhring G
Leuk Res; 2010 Aug; 34(8):1002-6. PubMed ID: 20022374
[TBL] [Abstract][Full Text] [Related]
18. [Cytogenetic characteristics of patients with multiple myeloma in China: analysis of 100 case].
Deng SH; Xu Y; Wang YF; Mai YJ; Liu XP; Zhao YZ; Zou DH; Wang Y; Qiu LG
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(24):1685-8. PubMed ID: 17825148
[TBL] [Abstract][Full Text] [Related]
19. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Implications of Monosomies in Patients With Multiple Myeloma.
Shin SY; Eom HS; Sohn JY; Lee H; Park B; Joo J; Jang JH; Lee MN; Kim JK; Kong SY
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):159-164.e2. PubMed ID: 28089441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
